Allergy Immunotherapy Market By Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy); By Allergy Type (Allergic Rhinitis, Asthma, Venom Allergy, Food Allergy, Others); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Allergy Immunotherapy Market: Prescription Tablets, Pediatric Expansion, and Long-Term Treatment Economics Reshape Allergy Care

The Global Allergy Immunotherapy Market is estimated to reach USD 2.77 billion in 2025 and is projected to grow to USD 5.86 billion by 2032, expanding at a CAGR of 11.3% during the forecast period, according to Strategic Market Research.

 

The Allergy Immunotherapy Market is moving from a predominantly clinic-administered extract business toward a broader mix of subcutaneous immunotherapy, regulated sublingual tablets, country-specific liquid formulations, and emerging food-allergy products. Revenue is generated through recurring allergen-extract sales, daily prescription tablets, prepared injection doses, administration visits, diagnostic testing, and specialist follow-up rather than one-time treatment events.

 

Subcutaneous immunotherapy, or SCIT, remains the established treatment channel because allergists can formulate injections for multiple clinically relevant allergens. Sublingual immunotherapy, or SLIT, is gaining commercial importance because daily tablets can be maintained at home after supervised initiation. Food oral immunotherapy represents a smaller and more operationally demanding segment in which desensitization, adverse-event management, treatment persistence, and specialist capacity have a greater effect on commercial uptake.

 

The market should therefore be measured through treated patient-years, tablet prescriptions, prepared SCIT doses, administration visits, persistence rates, reimbursement coverage, and prescriber access. Allergy prevalence alone significantly overstates commercially realizable demand. The supplied healthcare-pathway assessment similarly classifies the market as drug-driven, supported by testing and office-administration services, and identifies the absence of a reliable current national count of all U.S. immunotherapy patients.

 

Large Allergy Burden Produces a Much Smaller Immunotherapy-Eligible Population

Diagnosed allergic disease creates a substantial treatment funnel. In the United States, 25.2% of adults reported a diagnosed seasonal allergy in 2024. Among children younger than 18, the corresponding rate was 20.6%. Diagnosed food allergy affected 6.7% of adults and 5.3% of children. These figures support sustained demand for allergy consultations, antihistamines, nasal corticosteroids, diagnostic testing, emergency treatments, and immunotherapy evaluation, but they do not represent the number of patients eligible for AIT.

AIT generally becomes commercially relevant when symptoms remain clinically important despite avoidance measures and symptom-relieving medicines, the responsible allergen is confirmed through clinical history and sensitization testing, an appropriate product or extract is available, and the patient can commit to long-term treatment. Referral to an allergist or ear, nose, and throat specialist is another important conversion point. The difference between diagnosed prevalence and initiated treatment remains one of the largest uncertainties in top-down market forecasting.

The frequently cited estimate that approximately 2.6 million Americans receive allergen immunotherapy annually is traceable to a 2019 peer-reviewed publication. It remains useful as a historical utilization reference, but it should not be presented as a current 2026 patient count without newer claims or prescription evidence. It also covers AIT for allergic rhinitis and asthma rather than every respiratory, venom, animal, or food-allergy immunotherapy pathway.

 

SCIT Retains the Largest Treatment Infrastructure

SCIT remains commercially important because it can address pollens, house dust mites, molds, animal allergens, insects, and other selected allergen sources. The U.S. Food and Drug Administration regulates injectable allergen extracts used for allergy diagnosis and treatment. The FDA also distinguishes standardized extracts from the wider range of nonstandardized products used by specialist practices.

The SCIT business model extends beyond extract manufacturing. Specialist practices prepare patient-specific doses, supervise escalation, administer maintenance injections, and manage adverse-reaction risk. U.S. Medicare billing guidance separately recognizes allergenic-extract preparation and professional administration through codes including 95165, 95115, and 95117. This creates recurring provider revenue but also links market growth to clinic staffing, appointment capacity, reimbursement rules, and patients’ ability to attend repeated visits.

SCIT’s clinical structure can support persistence because patients return to a clinic, but the visit burden also contributes to non-initiation and discontinuation. A German prescription-database analysis of house dust mite immunotherapy reported three-year adherence of 55.0% for SCIT compared with 30.3% for SLIT tablets in the studied cohorts. These results are observational and cannot be generalized to every product or country, but they demonstrate that the nominal three-year treatment course is not equivalent to three realized years of revenue. Persistence programs, appointment convenience, patient education, and practice workflow are therefore commercial capabilities rather than secondary support services.

 

Prescription SLIT Tablets Are Capturing Higher-Value Growth

Prescription SLIT tablets are becoming the strongest visible growth segment within regulated respiratory immunotherapy. They reduce routine injection visits, simplify standardized dosing, and allow maintenance therapy at home. Their commercial limitations include single-allergen positioning, daily adherence requirements, local oral reactions, first-dose supervision, product-specific age restrictions, and dependence on pharmacy coverage.

The U.S. regulated tablet category remains concentrated around products for grass pollen, short ragweed pollen, and house dust mites. ODACTRA’s label was expanded in February 2025 to include children aged five through 11, extending the house dust mite tablet indication across patients aged five through 65. Pediatric eligibility matters commercially because allergic rhinitis often begins early, while a longer lifetime treatment horizon increases the value of prescriber education and early referral.

Company reporting provides the clearest direct evidence of the value shift. ALK reported that tablet sales increased 17% to DKK 3.335 billion in 2025, while combined SCIT and SLIT-drop sales increased 5% to DKK 2.145 billion. These are supplier-level figures rather than total-market estimates, but they show materially faster momentum in standardized tablets than in the company’s traditional extract and drop portfolio.

The trend continued during the first quarter of 2026. ALK reported tablet revenue of DKK 1.004 billion, an increase of 18%, with tablet sales in both Europe and North America growing 26%. The company attributed the performance to expanding patient and prescriber bases, while prescriptions for children and adolescents increasingly contributed to growth. Combined SCIT and SLIT-drop sales also rose 15%, partly because of shipment timing to China. The China result should be interpreted as a supplier shipment indicator rather than direct evidence of equivalent patient-level growth.

 

Pollen Immunotherapy Benefits from Strong Evidence and Longer Allergy Seasons

Pollen allergy remains a core commercial segment because symptoms recur predictably and affect work, sleep, school performance, medication consumption, and healthcare utilization. Grass, ragweed, birch-related tree pollen, and other seasonal allergens support both SCIT and standardized SLIT products.

Clinical studies of pollen AIT have reported approximately 30% to 40% reductions in combined symptoms and rescue-medication requirements during three years of therapy. Evidence also indicates that a minimum treatment duration of about three years is generally needed for sustained clinical benefit after discontinuation. These effects are not equivalent to complete symptom elimination, but they create a differentiated value proposition compared with medicines that are used only during allergen exposure.

Long-term benefit improves the economic case for AIT, while the three-year commitment raises the importance of adherence. Manufacturers and providers benefit when patients begin treatment before a predictable pollen season, continue through maintenance, and renew prescriptions across multiple years. Revenue can be lost when patients expect immediate relief, stop during symptom-free periods, or fail to perceive incremental improvement.

European reimbursement is expanding the addressable tablet population. In August 2025, the National Institute for Health and Care Excellence recommended betula verrucosa, marketed as ITULAZAX, for eligible adults with moderate-to-severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group. Separately, pediatric approval for the product was announced across 17 European countries in April 2025 following a Phase III trial involving 952 children and adolescents aged five to 17.

 

House Dust Mite Allergy Supports Year-Round Prescription Demand

House dust mite immunotherapy differs commercially from seasonal pollen therapy because exposure and symptoms can occur throughout the year. This can support regular prescription demand, continuous patient monitoring, and a stronger rationale for initiating treatment outside a narrow pollen-season window.

The supplied estimate of 65 million to 130 million people with house dust mite allergy worldwide should be treated as an indicative range rather than a precise market population. Published sensitization and disease estimates vary by geography, age, housing, climate, diagnostic method, and whether studies measure sensitization, allergic rhinitis, asthma, or clinically confirmed HDM allergy. Sensitization alone does not establish treatment eligibility.

Commercial expansion is more reliably demonstrated through product labels and payer decisions. ODACTRA’s U.S. pediatric expansion widened the eligible age range, while NICE recommended 12 SQ-HDM SLIT in March 2025 for a defined group of patients with persistent house dust mite allergic rhinitis. NICE did not recommend the same product for adult house dust mite allergic asthma under that appraisal, showing that reimbursement remains indication-specific even when a product is approved and clinically established.

This selective access affects forecasting. The commercially addressable HDM population is not every sensitized patient. It is the subgroup with confirmed clinical relevance, persistent disease despite symptom-relieving treatment, appropriate age and indication, specialist evaluation, payer authorization, and willingness to use daily therapy.

 

Animal-Dander and Cockroach Immunotherapy Remain Evidence-Constrained Niches

Animal-dander allergy creates a meaningful treatment need because avoidance can conflict with pet ownership, occupation, housing conditions, and family preferences. Cat allergens such as Fel d 1 are better characterized than many dog allergens, but clinical evidence for animal-dander AIT remains smaller and less consistent than the evidence for grass pollen or house dust mites.

The supplied claim that approximately 80% of animal-dander patients achieve significant improvement after three to five years should not be used as a universal market success rate. Reviews of available studies identify small patient populations, heterogeneous extracts, differing endpoints, and inconsistent outcomes, particularly for dog allergy. Animal-dander immunotherapy is commercially relevant within individualized SCIT formulations, but it is not yet supported by the standardized evidence base or broad regulated tablet availability seen in major pollen and HDM segments.

Cockroach allergen exposure is particularly important in urban asthma, lower-quality housing, and warm or humid environments. Published estimates of sensitization vary widely because studies examine different populations, including the general population, exposed households, children, and inner-city patients with asthma. The reported ranges of 17% to 41% in broader populations and higher rates among urban asthma cohorts should therefore be labeled as study-specific sensitization estimates, not global prevalence.

Cockroach allergy currently represents more of an unmet diagnostic, environmental-control, and research opportunity than a mature standardized immunotherapy category. Variability in extracts, allergen exposure, study design, and clinical evidence restricts broad product adoption. Market forecasts should avoid converting the percentage of homes with detectable cockroach allergens into an immunotherapy patient pool.

 

Food OIT Expands the Market but Raises Safety and Operating Costs

Food OIT is designed to raise the amount of allergen that a patient can tolerate while treatment continues. Its principal commercial value is protection against accidental exposure rather than unrestricted consumption or guaranteed permanent remission. Desensitization and sustained unresponsiveness must be separated because patients who tolerate a food during daily dosing may lose protection when therapy is stopped.

Across published food-OIT studies, approximately 71% to 90% of patients who reach maintenance have retained desensitization, but outcomes differ substantially by allergen, age, starting threshold, dose, treatment duration, endpoint, and study population. Sustained unresponsiveness is generally lower and more variable. A 2025 review reported that sustained unresponsiveness can approach 78% in peanut-allergic infants and toddlers under four in selected early-intervention studies, but this should not be generalized to older children, adolescents, other allergens, or routine clinical practice.

Adverse reactions remain a major commercial constraint. Gastrointestinal symptoms, oral itching, vomiting, and mild-to-moderate allergic reactions are common during treatment. A meta-analysis estimated new-onset eosinophilic esophagitis in up to 2.7% of patients undergoing food OIT. The supplied figure of approximately 3% is therefore directionally supported, although diagnosis and reporting practices differ across studies.

The suggested comparison of a 1% severe-reaction rate in preschool children with approximately 15% in adolescents should not be presented as a general age-based risk rule. Severe-event rates depend on the allergen, protocol, dose, asthma control, infections, exercise, missed doses, and study definitions. Younger children are receiving growing research attention because early treatment may improve desensitization and remission outcomes, but age alone does not remove the need for specialist supervision and risk management.

 

PALFORZIA’s Exit Shows That Approval Does Not Guarantee Commercial Sustainability

PALFORZIA established a regulated U.S. food-OIT pathway for peanut allergy, but Stallergenes Greer has announced that commercialization will end on July 31, 2026. The company states that the voluntary discontinuation is not related to product safety, quality, or efficacy.

The exit is strategically important because it separates clinical validation from commercial viability. Branded food OIT requires diagnosis, oral food challenges, supervised dose escalation, emergency preparedness, patient and caregiver education, daily maintenance, reimbursement support, and long-term persistence. High unmet need does not automatically offset the operational burden placed on families, specialists, pharmacies, and payers.

At the same time, food-allergy development is continuing through alternative formats. In April 2026, ALK reported positive Phase II results for a once-daily peanut SLIT tablet in a randomized study of 150 patients. At the highest dose, 49% tolerated 300 mg of peanut protein compared with 18% on placebo, while the company reported no treatment-related anaphylaxis or treatment-related serious adverse events. Phase III initiation is expected in late 2026, subject to regulatory feedback. These findings are company-reported clinical results rather than an approval forecast, but they support continued investment in more convenient food-allergy delivery models.

 

Immune-Tolerance Science Supports Product Differentiation

AIT’s commercial differentiation comes from its potential to alter allergen responsiveness rather than only suppress symptoms during exposure. Treatment increases allergen-specific regulatory immune activity, promotes protective IgG4 antibodies, and reduces the activation of mast cells, basophils, eosinophils, and other inflammatory pathways.

These mechanisms matter commercially when they produce fewer symptoms, lower rescue-medication use, reduced exacerbations, or sustained post-treatment benefit. Mechanistic biomarkers alone are not sufficient for market adoption. Regulators and payers require product-specific evidence because extracts, allergen concentrations, dosing units, formulations, and clinical endpoints are not interchangeable across manufacturers.

This requirement is encouraging greater standardization of symptom-medication scores, allergen challenge procedures, potency measurement, and pediatric trial design. It also supports component-resolved diagnostics and more precise identification of the allergen responsible for clinically meaningful symptoms. Better selection could improve response rates and reduce the number of patients beginning long courses of poorly matched treatment.

 

Adherence and Specialist Access Determine Realized Revenue

The commercial funnel narrows at diagnosis, referral, treatment initiation, escalation, and long-term maintenance. A nationwide French study linked dispensing and healthcare-insurance data to evaluate liquid SLIT in 112,492 treated patients, providing one of the strongest publicly available observations of real-world treatment use. The cohort is not an annual French patient count, but it confirms that liquid SLIT remains an established treatment channel in selected European markets.

Real-world evidence also supports sustained clinical benefits. The REACT retrospective study found longer-term effectiveness associated with AIT in routine care, complementing randomized trial evidence. Such datasets can strengthen payer discussions, but they do not remove the need to account for confounding, country-specific prescribing, and incomplete adherence.

Home dosing reduces clinic visits but transfers responsibility for daily persistence to patients and caregivers. Clinic-administered SCIT creates more structured contact but adds travel, time, and provider-capacity constraints. Successful suppliers increasingly need patient-support systems, refill monitoring, prescriber education, dose-escalation guidance, adverse-event management, and evidence showing that patients remain on treatment long enough to realize clinical and economic value.

 

North America Combines a Large Patient Funnel with a Concentrated Specialist Channel

North America offers a large diagnosed allergy population, regulated SLIT products, extensive SCIT use, public and commercial insurance, and active food-allergy development. U.S. reimbursement for SCIT preparation and administration supports recurring provider economics, while pediatric label expansion is increasing the addressable population for branded tablets.

The region’s limitations include inconsistent insurance coverage, out-of-pocket costs, specialist concentration, long travel distances, and variable acceptance of multi-year therapy. Off-label SLIT drops also create a different competitive environment from FDA-approved tablets because formulation, dosing, reimbursement, and evidence are not standardized in the same way.

North American growth is likely to remain split between the established SCIT channel and higher-growth prescription tablets. Food immunotherapy will depend more heavily on whether developers can reduce up-dosing burden, adverse reactions, restricted-distribution requirements, and treatment discontinuation.

 

Europe Benefits from Reimbursement Expansion and Multiple Delivery Models

Europe has broader experience with SCIT, liquid SLIT, tablets, named-patient preparations, and country-specific reimbursement. France provides large-scale real-world evidence for liquid SLIT, while Germany offers extensive prescription and adherence data. England’s 2025 NICE decisions for house dust mite and birch-related tree-pollen tablets provide recent examples of public-payer support for defined patient groups.

European growth is not uniform. Product authorization, evidence requirements, list prices, rebates, specialist pathways, and reimbursement differ by country. ALK’s 2026 outlook identifies continued tablet-volume growth but also recognizes the possible effect of European price and rebate adjustments. Higher tablet mix can support supplier margins, while payer negotiation can reduce realized price.

Pediatric access is a particularly important growth area. During 2025, pediatric house dust mite and tree-pollen launches expanded across multiple European markets. Greater prescribing among children and adolescents can increase long-term patient-years, but adoption depends on referral, testing, family acceptance, and the ability to maintain treatment during symptom-free periods.

 

Asia-Pacific Growth Depends on Specialist Capacity and Standardization

Asia-Pacific includes large populations exposed to house dust mites, pollens, molds, cockroach allergens, and urban air-quality factors that can worsen respiratory allergy. The region offers significant long-term demand, but clinical practice, product authorization, reimbursement, diagnostic capacity, and specialist density vary substantially.

China is commercially important for injectable immunotherapy, although supplier shipments should not be confused with national treatment volume. ALK reported that Q1 2026 growth in its SCIT and SLIT-drop category was supported mainly by SCIT shipments to China. This indicates distribution demand and supplier activity, but inventory timing may differ from patient initiation.

Japan, China, South Korea, Australia, and other markets are likely to develop through different mixes of standardized tablets, imported extracts, locally manufactured products, and specialist-administered therapy. Regional forecasts require country-level data rather than applying European or U.S. utilization assumptions across Asia-Pacific.

 

Competitive Positioning Is Shifting Toward Evidence, Convenience, and Patient Retention

The competitive landscape includes specialist allergy companies such as ALK-Abelló and Stallergenes Greer, injectable-extract manufacturers, national and regional allergen suppliers, pharmaceutical partners, diagnostic companies, pharmacies, and allergy practices.

ALK estimated that 3.1 million people were treated with its products in 2025, approximately 500,000 more than in 2024. This company-specific figure includes its broader allergy portfolio and should not be presented as a total global AIT patient count. It nevertheless provides direct evidence that patient reach is expanding within a major supplier platform.

Competitive advantage increasingly depends on five factors: regulated and standardized products; pediatric and geographic label breadth; reimbursement support; convenient dosing; and retention over a multi-year course. SCIT suppliers retain advantages in allergen breadth and individualized formulations. Tablet companies benefit from standardized evidence, pharmacy distribution, and home maintenance. Food-allergy developers must show that convenience and safety improvements are sufficient to create sustainable adoption.

 

Allergy Immunotherapy Market Outlook

The Allergy Immunotherapy Market is expanding through a transition from symptom control toward allergen-specific, disease-modifying treatment. The most credible near-term growth indicators are regulated SLIT-tablet sales, pediatric label expansion, public-payer recommendations, greater use of real-world evidence, and continued investment in more convenient food-allergy formulations.

SCIT will remain a central revenue channel because of its allergen breadth, physician familiarity, and established reimbursement infrastructure. Prescription SLIT tablets are positioned to capture higher growth where standardized evidence, pediatric indications, and reimbursement align. Liquid SLIT will remain commercially important in markets with established prescribing and regulatory pathways. Food OIT and food SLIT offer substantial unmet-need potential but face greater safety, adherence, and operating-model risk.

Forecasting should separate total allergy prevalence from confirmed sensitization, clinical eligibility, specialist referral, payer approval, treatment initiation, and long-term persistence. Suppliers that expand the diagnosed-to-treated funnel while improving patient retention are likely to capture more value than companies relying only on prevalence growth or product approval

 

Allergy Immunotherapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.77 Billion
Revenue Forecast in 2032	USD 5.86 Billion
Overall Growth Rate	CAGR of 11.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Treatment Type	Subcutaneous Immunotherapy; Sublingual Immunotherapy
By Allergy Type	Allergic Rhinitis; Asthma; Venom Allergy; Food Allergy; Others
By Route of Administration	Oral; Injectable
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online; Specialty Clinics
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising Allergy Disease Burden	Increasing prevalence of allergic rhinitis, asthma, food allergies, and other allergic conditions is expanding the patient pool requiring specialist evaluation and long-term treatment.
Market Drivers – Growth of Sublingual Immunotherapy Tablets	Increasing adoption of regulated SLIT tablets is supporting home-based treatment models, pediatric expansion, and improved patient convenience compared with clinic-based injections.
Market Drivers – Focus on Disease-Modifying Allergy Treatment	Growing preference for therapies that provide long-term immune tolerance rather than only symptom relief is strengthening demand for allergen-specific immunotherapy.
Customization Option	Available upon request